IUGNF (Imugene) Total Receivables: $10.02 Mil (As of Dec. 2025)


IUGNF Imugene Ltd IUGNF
30 GF Score
Price $0.10
! 4 Warning Signs
View Full Analysis

What is Imugene Total Receivables?

Imugene IUGNF 30 Total Receivables is $10.02 Mil as of Dec. 2025. GuruFocus rates IUGNF with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Imugene's Total Receivables for the quarter that ended in Dec. 2025 was $10.02 Mil.

Imugene Total Receivables Historical Data

* Premium members only.

The historical data trend for Imugene's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene Total Receivables Chart

Imugene Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.09 8.97 7.28 8.38 6.52

Imugene Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.65 8.38 11.50 6.52 10.02
IUGNF
30GF Score
Imugene Ltd IUGNF
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imugene Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $10.02 Mil mean?
Imugene (IUGNF) has a Total Receivables of $10.02 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Imugene and its competitors.
Is Imugene's Total Receivables too high?
Imugene's current Total Receivables is $10.02 Mil. Overall, Imugene has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Imugene's Total Receivables compare to VRTX and REGN?
Imugene's Total Receivables of $10.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Imugene and its competitors. Imugene's current Total Receivables is $10.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imugene stock overvalued right now?
Imugene (IUGNF) has a current Total Receivables of $10.02 Mil. The current Total Receivables is $10.02 Mil. Imugene's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Imugene (IUGNF), the current Total Receivables is $10.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imugene Business Description

Other Exchanges ILA:GermanyIMU:Australia
Address 4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
30GF Score

Get the complete analysis for IUGNF

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price